Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
219
-
Total 13F shares, excl. options
-
94.9M
-
Shares change
-
+13.4M
-
Total reported value, excl. options
-
$4.36B
-
Value change
-
+$625M
-
Put/Call ratio
-
1.39
-
Number of buys
-
126
-
Number of sells
-
-110
-
Price
-
$46.00
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q2 2017
281 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q2 2017.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 219 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.9M shares
of 99.6M outstanding shares and own 95.23% of the company stock.
Largest 10 shareholders include FMR LLC (13.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.17M shares), VANGUARD GROUP INC (6.92M shares), JANUS HENDERSON GROUP PLC (5.37M shares), BlackRock Inc. (4.8M shares), PERCEPTIVE ADVISORS LLC (3.58M shares), BB BIOTECH AG (3.45M shares), FRANKLIN RESOURCES INC (3.38M shares), WELLINGTON MANAGEMENT GROUP LLP (3.03M shares), and Invesco Ltd. (2.96M shares).
This table shows the top 219 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.